Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults

To determine the safety & immunogenicity of a potential vaccine against meningococcal B disease

Inclusion Criteria:

• Healthy 18-25 year olds

Exclusion Criteria:

• Prior history of vaccination with any meningococcal vaccine
• Prior history of any invasive meningococcal disease